List of Excipients in Branded Drug PEGASYS

PEGASYS Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

PEGASYS is peginterferon alfa-2a, a PEGylated recombinant interferon biologic developed by Roche for chronic hepatitis C and chronic hepatitis B. Its formulation uses a conventional liquid-protein strategy: buffered aqueous solution, sodium chloride for tonicity, polysorbate 20 for interfacial protection, and benzyl alcohol in labeled presentations. The strongest commercial opportunities are unlikely to come from copying the legacy excipient list. They are more likely to arise from preservative-free presentations, improved container-closure systems, lower injection burden, biosimilar formulations, and regional supply of high-purity excipients.

What excipients are used in PEGASYS?

PEGASYS is supplied as a sterile injectable solution containing peginterferon alfa-2a. FDA labeling identifies sodium chloride, polysorbate 20, benzyl alcohol, sodium acetate trihydrate, acetic acid, and water for injection as formulation components, with pH adjustment used to control product stability.[1]

PEGASYS excipient profile

Formulation function	PEGASYS component	Commercial or technical purpose
Active biologic	Peginterferon alfa-2a	Long-acting interferon alfa-2a
Tonicity control	Sodium chloride	Reduces injection discomfort and helps match osmolality
Surfactant	Polysorbate 20	Limits adsorption and aggregation at air-liquid and container interfaces
Buffer system	Sodium acetate trihydrate and acetic acid	Maintains formulation pH
Preservative	Benzyl alcohol in labeled presentations	Supports multidose or repeated-use presentation requirements
Vehicle	Water for injection	Injectable solvent

The formulation is designed around the instability risks of a PEGylated protein. These include aggregation, surface adsorption, oxidation, agitation sensitivity, and interaction with the syringe or vial system. Polysorbate 20 is particularly important because protein therapeutics can lose potency or form particles when exposed to air-liquid interfaces, silicone oil, glass, elastomeric components, or shipping stress.

PEGASYS is available in prefilled syringe and vial presentations in strengths including 135 micrograms and 180 micrograms. The precise excipient composition, container system, fill volume, and preservative status must be evaluated by presentation rather than assumed to be identical across all markets.[1,2]

How does the PEGASYS formulation strategy work?

PEGASYS uses a liquid formulation rather than a lyophilized product. That approach reduces reconstitution steps and supports ready-to-use subcutaneous administration. The tradeoff is a larger stability burden during refrigerated storage, transport, and handling.

Why polysorbate 20 matters

Polysorbate 20 is a nonionic surfactant used in many protein formulations. It can reduce adsorption of peginterferon alfa-2a to glass, plastic, and other surfaces. It also limits stress-induced aggregation during filling, shipping, and injection.

The commercial risk is that polysorbate degradation can generate peroxides and free fatty acids. Those degradation products can create particles, alter protein quality, or affect visible appearance. A biosimilar developer cannot treat polysorbate 20 as an interchangeable commodity. Supplier grade, peroxide burden, hydrolysis profile, storage conditions, and lot-to-lot variability can affect the finished product.

Why the acetate buffer matters

The sodium acetate and acetic acid system controls pH in the range used for PEGASYS stability. Buffer selection affects protein conformation, aggregation, deamidation, oxidation, injection tolerability, and compatibility with the syringe and stopper.

A follow-on developer that changes the buffer system may need a broader analytical comparability package. The change can be commercially attractive if it improves long-term stability or reduces degradation, but it increases development and regulatory risk.

Why benzyl alcohol matters

Benzyl alcohol is a preservative used in some injectable biologic formulations. Its presence creates a tradeoff between multidose-use convenience and patient-population restrictions. Benzyl alcohol exposure is a recognized concern in neonates and young infants, although PEGASYS is not a routine neonatal therapy.

A preservative-free, single-dose presentation could support a differentiated product strategy. It could also remove a formulation component that some hospitals and specialty pharmacies prefer to avoid. The cost is higher packaging consumption, tighter microbiological controls, and potentially more complex commercial logistics.

What patents protect PEGASYS and its excipient formulation?

PEGASYS is a biologic, so its U.S. regulatory protection is not organized through the small-molecule Orange Book framework. Biologic reference products are recorded in the FDA Purple Book, while patent disputes involving biosimilars are handled under the Biologics Price Competition and Innovation Act patent-exchange and litigation framework.[3,4]

Orange Book status

PEGASYS does not have the same Orange Book listing structure as a conventional small-molecule drug. A search strategy focused only on Orange Book patents will not capture the relevant biologic patent, formulation, manufacturing, or platform rights.

Relevant rights may include:

• PEGylation chemistry and linker patents
• recombinant interferon production patents
• protein sequence or host-cell patents
• formulation and stability patents
• syringe or vial configuration patents
• manufacturing and purification methods
• method-of-use patents for hepatitis B or hepatitis C
• regulatory exclusivity and pediatric exclusivity

Many foundational PEGylated interferon rights were filed decades ago. Their practical value depends on claim scope, terminal disclaimers, continuations, national-phase coverage, and whether any later patent covers a commercially relevant presentation.

Patent expiration and loss of exclusivity

The core commercial protection for PEGASYS has largely moved beyond the original launch-era exclusivity period. FDA approved PEGASYS in 2002 for chronic hepatitis C, followed by additional hepatitis C and hepatitis B indications.[1,5] The standard U.S. reference-product biologic exclusivity period for a product approved under the modern BPCIA framework is 12 years, but PEGASYS predates that statutory framework. Its commercial position therefore depends more on patent status, manufacturing complexity, brand supply, and the limited size of the remaining market than on current reference-product exclusivity.

A precise live-patent conclusion requires claim-by-claim review in the United States and each target jurisdiction. The key commercial point is that an excipient supplier or biosimilar developer should not assume that the historical PEGASYS formulation itself remains protected by a broad, enforceable formulation patent.

Does PEGASYS have Orange Book patents or Paragraph IV risk?

PEGASYS is not exposed to the standard abbreviated new drug application Paragraph IV pathway used for small molecules. A conventional generic cannot rely on an ANDA to substitute for a complex biologic reference product.

Biosimilar pathway

A competing peginterferon alfa-2a product would generally be evaluated through the U.S. 351(k) biosimilar pathway or a jurisdiction-specific biologic pathway. The applicant would need to establish high similarity to the reference product through:

• Structural characterization of the pegylated interferon
• Comparative biological activity
• Impurity and aggregate profiling
• Glycosylation and conjugation analysis
• Stability studies
• Immunogenicity assessment
• Comparative pharmacokinetics and, where required, clinical data

The excipient system is part of the comparability package. A biosimilar may use different excipients, but the changes must be justified through analytical, pharmacological, clinical, and safety evidence.

Patent litigation risk

Potential disputes could involve:

1. PEGylation method patents.
2. Protein production or purification claims.
3. Formulation stability claims.
4. Prefilled syringe or container-closure claims.
5. Manufacturing process claims.
6. Method-of-use claims that remain relevant in chronic hepatitis B.

Unlike an ANDA Paragraph IV challenge, a biosimilar developer must analyze the BPCIA patent-exchange process and the reference sponsor’s listed patents in the Purple Book-related disclosure framework. A licensing agreement or settlement could shape launch timing even where the core formulation patent has expired.

What formulation patents could protect a PEGASYS follow-on product?

The highest-value formulation claims would protect measurable performance advantages rather than merely recite the same excipients.

Potential claim categories

Claim category	Example commercial objective
Preservative-free liquid	Eliminate benzyl alcohol and expand institutional acceptance
Improved surfactant system	Reduce polysorbate oxidation and particle formation
Alternative surfactant	Use poloxamer or another excipient where comparability is supportable
Low-particle formulation	Improve visible and subvisible particle profile
Enhanced refrigerated stability	Extend shelf life or reduce wastage
Room-temperature excursion stability	Lower distribution and pharmacy handling costs
Low-silicone syringe system	Reduce protein interaction with device lubricants
Dual-chamber or reconstitution system	Improve long-term stability through separation of components
Concentrated formulation	Reduce injection volume
Autoinjector-compatible formulation	Improve self-administration and adherence

A formulation patent is stronger when it links the composition to unexpected stability, lower aggregation, improved immunogenicity profile, reduced injection pain, or a meaningful shelf-life gain. A patent that simply substitutes one conventional buffer or surfactant for another may face obviousness and enablement challenges.

What are the commercial opportunities for PEGASYS excipients?

The opportunity is divided between direct product competition and supply-chain value capture.

1. High-purity polysorbate 20 supply

Polysorbate 20 is the most strategically important excipient in the PEGASYS formulation. Suppliers can differentiate through:

• Low peroxide and aldehyde content
• Controlled fatty-acid distribution
• Reduced subvisible particle formation
• Better lot consistency
• Defined oxidation monitoring
• Extractables and leachables documentation
• Global GMP and regulatory support

A supplier able to provide a biologic-grade polysorbate with strong stability data can capture value from biosimilar and lifecycle-management programs. The opportunity is greater than commodity volume because biologic manufacturers often qualify multiple suppliers only slowly.

2. Preservative-free PEGASYS-like products

A preservative-free presentation could target hospital systems, specialty pharmacies, and markets that prefer single-dose administration. The product would need a validated sterile single-use container and a robust microbial-control strategy.

The commercial benefit would be strongest where benzyl alcohol avoidance is valued or where multidose packaging provides little operational advantage. The product would face higher unit packaging costs and would need to demonstrate comparable stability and usability.

3. Device-compatible formulations

PEGASYS is administered subcutaneously. A follow-on product compatible with an autoinjector, safety syringe, or low-dead-volume device could reduce administration burden and improve dose delivery.

The development challenge is interaction among:

• Protein solution
• Silicone oil
• Needle adhesive
• Elastomeric plunger
• Glass or polymer barrel
• Surfactant degradation products
• Mechanical stresses during injection

A device-linked formulation patent could provide stronger commercial differentiation than an excipient-only patent if the combination delivers a measurable performance benefit.

4. Cold-chain and shelf-life improvements

PEGASYS requires controlled storage according to its approved labeling. A follow-on product with validated temperature-excursion stability could reduce pharmacy losses and simplify distribution in emerging markets.

The most valuable claim would combine a specific composition with demonstrated stability after temperature cycling, agitation, freeze-thaw exposure, or extended storage. A longer shelf life could improve tender competitiveness even if the active ingredient is not clinically differentiated.

5. Regional excipient manufacturing

Demand for biologic-grade excipients is increasing as biosimilar manufacturing expands in Asia, Latin America, the Middle East, and Eastern Europe. Local or regional manufacturers can compete by offering:

• Qualified polysorbate 20 and acetate-buffer components
• GMP documentation
• Pharmacopoeial compliance
• Dual sourcing
• Shorter delivery times
• Lower import exposure
• Technical support for formulation transfer

The barrier is qualification, not basic chemical synthesis. A new supplier must generate enough consistency and documentation to pass customer audits and regulatory review.

How strong is the PEGASYS patent estate?

The core PEGASYS patent estate is likely less commercially powerful than it was during the product’s launch period. The remaining value is more likely to sit in specific process, formulation, device, or use claims than in broad composition-of-matter protection.

Patent-strength assessment

Factor	Assessment
Core active-ingredient protection	Limited relative to launch-era position because of product age
PEGylation technology	Potentially relevant, but dependent on claim scope and expiration
Excipient formulation claims	Potential value if tied to unexpected stability or performance
Method-of-use protection	More relevant in chronic hepatitis B than in hepatitis C, where direct-acting antivirals dominate
Manufacturing barriers	Meaningful due to protein characterization, PEG conjugation, impurity control, and scale-up
Device protection	Potentially valuable for differentiated injection systems
Biosimilar entry barrier	Moderate to high technically, but lower if the product is commercially niche
Market barrier	Significant because hepatitis C treatment has shifted to oral direct-acting antivirals

Patent strength and commercial strength are separate. A technically difficult biosimilar may still have limited value if the remaining market is small or if physicians have shifted to competing treatment classes.

When does PEGASYS lose commercial exclusivity?

PEGASYS lost the commercial advantages associated with launch-era exclusivity long ago, but the timing of a competing product depends on jurisdiction-specific patents, regulatory approval, supply readiness, and litigation.

United States

The U.S. pathway for a follow-on biologic is biosimilar approval under section 351(k), not an ANDA with Paragraph IV certification. A biosimilar sponsor must assess reference-product patents, manufacturing patents, formulation rights, and relevant use claims before launch.

European Union

The European Medicines Agency biosimilar pathway is available for products with sufficient reference-product data and a scientifically supportable comparability package. European national patent rights, supplementary protection certificates, litigation, and market-specific reimbursement determine launch timing.

Other markets

Countries with established biologic or biosimilar pathways may offer earlier entry if patent enforcement is narrower or if the reference product has limited commercial distribution. The main barriers remain analytical comparability, local regulatory requirements, reimbursement, and access to qualified PEGylated interferon manufacturing.

How does PEGASYS compare with competing interferon products?

PEGASYS competes more directly with peginterferon alfa-2b than with current hepatitis C direct-acting antivirals. Its commercial position differs by indication.

Product or class	Active modality	Excipient and device opportunity	Commercial position
PEGASYS	Peginterferon alfa-2a	Preservative-free syringe, stability, device compatibility	Legacy interferon product; chronic hepatitis B remains the more relevant market
PegIntron	Peginterferon alfa-2b	Alternative protein and PEG architecture; formulation and injection systems	Historical interferon competitor
Direct-acting antivirals	Oral small molecules	Tablet excipients, solid-state control, combination products	Dominant hepatitis C treatment class
Conventional interferon alfa	Non-PEGylated interferon	Lower-cost injectable formulations	Shorter dosing interval and narrower commercial appeal
Biosimilar peginterferon	Follow-on biologic	High-purity excipients, analytical comparability, device differentiation	Potentially attractive in price-sensitive and hepatitis B markets

The largest commercial threat to PEGASYS is not an excipient-matched biosimilar. It is therapeutic substitution by oral hepatitis C regimens. That fact limits the value of a formulation-only lifecycle program for hepatitis C but leaves narrower opportunities in chronic hepatitis B and selected global markets.

What manufacturing and intellectual-property barriers affect PEGASYS follow-on products?

Manufacturing complexity is a material barrier even where composition patents are weak.

Key technical barriers

• Recombinant interferon expression and purification
• Site-controlled or reproducible PEG conjugation
• Removal of unconjugated interferon and free PEG
• Control of high-molecular-weight species
• Measurement of potency and antiviral activity
• Control of oxidation and deamidation
• Subvisible particle monitoring
• Container-closure compatibility
• Sterile filling of a low-dose biologic
• Stability under agitation and temperature excursions

The active concentration is low, so small changes in adsorption or aggregation can materially affect delivered dose. A follow-on developer also must establish a product-specific analytical fingerprint for PEG chain distribution, conjugation ratio, charge variants, potency, and impurities.

What licensing deals could create value around PEGASYS?

Licensing opportunities are more likely to involve technology and supply than the original PEGASYS brand.

Attractive licensing targets

1. Pegylation platform licenses for interferon or related cytokines.
2. High-purity polysorbate 20 supply agreements with technical support.
3. Preservative-free injectable formulation technology.
4. Autoinjector and low-dead-volume syringe systems.
5. Analytical methods for PEG distribution and conjugate characterization.
6. Regional manufacturing rights for emerging markets.
7. Biosimilar development partnerships with local biologics manufacturers.
8. Cold-chain reduction and temperature-excursion stability technology.

A commercial agreement should define ownership of formulation improvements, access to stability data, regulatory support obligations, field-of-use restrictions, and rights to substitute excipient suppliers. Control of the formulation package can be more valuable than control of the excipient itself.

What generic launch risks exist for a PEGASYS follow-on product?

A lower-priced product faces five principal launch risks:

• The hepatitis C market has shifted toward oral direct-acting antivirals.
• Chronic hepatitis B treatment guidelines may favor other long-term therapies.
• Biosimilar development costs may exceed the addressable market.
• Reference-product and manufacturing patents may remain relevant in specific countries.
• Physicians and payers may require extensive interchangeability or substitution evidence.

The strongest launch scenario is a biosimilar or improved peginterferon product aimed at chronic hepatitis B, price-sensitive public tenders, and markets where oral alternatives are less accessible. A premium product based only on the same excipients as PEGASYS is less likely to support a durable price premium.

Key Takeaways

• PEGASYS uses a conventional liquid biologic formulation with polysorbate 20, acetate buffering, sodium chloride, and benzyl alcohol in labeled presentations.
• Polysorbate 20 quality and degradation control are the most commercially relevant excipient issues.
• PEGASYS is a biologic and does not follow the standard Orange Book or Paragraph IV framework.
• Biosimilar competition requires a 351(k) or comparable biologic pathway, with extensive analytical comparability.
• The best formulation opportunities are preservative-free delivery, improved syringe compatibility, concentrated dosing, and stronger temperature-excursion stability.
• Hepatitis C market contraction limits the value of a PEGASYS lifecycle strategy, while chronic hepatitis B and emerging markets provide more credible opportunities.
• Manufacturing know-how, analytical characterization, and qualified excipient supply may be stronger barriers than remaining core composition patents.

FAQs

Can PEGASYS excipients be copied in a biosimilar?

Yes, a biosimilar may use the same excipients, but it must establish product comparability, stability, safety, and manufacturing control. Matching the excipient names alone does not establish biosimilarity.

Is polysorbate 20 the main formulation opportunity for PEGASYS?

It is the main excipient-related technical opportunity because its oxidation, hydrolysis, peroxide content, and particle profile can affect protein quality. Supplier qualification and degradation control are central commercial issues.

Could a preservative-free PEGASYS product receive patent protection?

Potentially. Protection would be stronger if the preservative-free formulation showed unexpected stability, reduced particles, improved tolerability, or device compatibility rather than merely removing benzyl alcohol.

Is PEGASYS still commercially attractive for hepatitis C?

The opportunity is limited because direct-acting antivirals have replaced interferon-based therapy in most hepatitis C treatment settings. Commercial potential is stronger in chronic hepatitis B, public tenders, and markets with restricted access to newer therapies.

What is the most valuable PEGASYS-related licensing asset?

The most valuable asset is likely a validated platform combining pegylated interferon manufacturing, analytical comparability, high-purity excipient supply, and a differentiated delivery device. A standalone excipient license is less defensible unless it delivers measurable stability or manufacturing advantages.

References

1. U.S. Food and Drug Administration. (2020). Pegasys (peginterferon alfa-2a) prescribing information. Genentech, Inc.

2. European Medicines Agency. (2023). Pegasys: Summary of product characteristics. Roche Registration GmbH.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-biological-products

5. U.S. Food and Drug Administration. (2002). FDA approves Pegasys for chronic hepatitis C. FDA news release.